{
    "clinical_study": {
        "@rank": "62228", 
        "arm_group": {
            "arm_group_label": "EPI-743", 
            "arm_group_type": "Experimental", 
            "description": "15 mg/kg EPI-743 to be administered three times per day for 1 year"
        }, 
        "brief_summary": {
            "textblock": "If effective, treatment with EPI-473 should result in a significant reduction in occurrence\n      of sepsis, metabolic crisis, hepatic failure and transfusion dependence."
        }, 
        "brief_title": "Phase 2 Study of EPI-743 in Children With Pearson Syndrome", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pearson Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Lipid Metabolism, Inborn Errors", 
                "Muscular Diseases", 
                "Mitochondrial Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genetically confirmed diagnosis of Pearson syndrome\n\n          -  Age less than 18\n\n          -  Availability of medical history for 12 months prior to enrollment\n\n          -  Abstention from use of CoQ10, vitamin E, lipoic acid and Idebenone 14 days   prior to\n             treatment with EPI-743\n\n        Exclusion Criteria:\n\n          -  Allergy to EPI-743, sesame oil or vitamin E\n\n          -  Clinical history of bleeding/ abnormal PT/PTT\n\n          -  Concurrent inborn errors of metabolism\n\n          -  Use of anticoagulant medications\n\n          -  Participation in any interventional study within 30 days of treatment\n\n          -  Use of erythropoietin 30 days prior to trial enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104336", 
            "org_study_id": "EPI743-13-024"
        }, 
        "intervention": {
            "arm_group_label": "EPI-743", 
            "description": "EPI-743 is the quinone oxidation product of alpha-tocotrienol", 
            "intervention_name": "EPI-743", 
            "intervention_type": "Drug", 
            "other_name": "Vincerinone (TM)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pearson", 
            "EPI743", 
            "EPI-743", 
            "Vincerinone", 
            "Mitochondrial disorder", 
            "Mitochondrial disease"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome", 
        "other_outcome": {
            "description": "Any adverse event greater than or equal to grade 3 that is deemed related to treatment with EPI-743 and not related to underlying disease", 
            "measure": "Number of Dose Limiting SAEs", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "mklein@edisonpharma.com", 
            "last_name": "Dr. Matthew Klein, MD, FACS", 
            "phone": "650-641-9211"
        }, 
        "overall_contact_backup": {
            "email": "ejohnson@edisonpharma.com", 
            "last_name": "Erin P. Johnson, BA", 
            "phone": "650-641-9212"
        }, 
        "overall_official": [
            {
                "affiliation": "Edison Pharmaceuticals", 
                "last_name": "Matthew Klein, MD, FACS", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Children\u2019s Hospital of Orange County", 
                "last_name": "Jose Abdenur, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurence of episodes of sepsis, metabolic crisis or hepatic faillure", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Transfusion avoidance", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Hematologic function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Neuromuscular function as assessed by Gross Motor Function Measure", 
                "measure": "Neuromuscular function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Disease severity as assessed by Newcastle Pediatric Mitochondrial Disease Scale", 
                "measure": "Disease severity", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Renal function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Hepatic function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Weight gain", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Hospitalizations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Pancreatic function as assessed by insulin requirement and hemoglobin A1c", 
                "measure": "Pancreatic function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Mortalilty", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Edison Pharmaceuticals Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Axio Research. LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Edison Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}